Patrick Godwin Okwute
Patrick Godwin Okwute has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Adegbesan Bukunola Oluyemisi
Obafemi Awolowo College of Health Sciences, Olabisi Onabanjo University, Sagamu Campus, Ogun State, Nigeria
1 shared publication - Adekunle Muiz Mofolorunso1 shared publication
- Esther Nkechi Ezima
Sagamu Campus, Olabisi Onabanjo University, Ago-Iwoye, OgunState, Nigeria
1 shared publication - Gideon Olamilekan Oluwatunase
Department of Anatomy, University of Medical Sciences, Ondo state, Nigeria; Department of Anatomy, Olabisi Onabanjo University, Ago-Iwoye, Ogun state, Nigeria
1 shared publication - Ifabunmi Oduyemi Osonuga
(1) Department of Physiology, Faculty of Basic Medical Sciences, Olabisi Onabanjo University, Sagamu Campus, Sagamu, Ogun State, Nigeria
1 shared publication - Samuel Oluwadare Olalekan
Department of Physiology, Olabisi Onabanjo University, Sagamu, Nigeria
1 shared publication
Latest Publications
- Open Access
- 3 June 2025
- Published by IntechOpen
Gut Microbiota Modulation in Parkinson’s Disease: Exploring Phytotherapy, Pharmacotherapy, and Precision Interventions
Parkinson’s disease (PD) is a progressive neurodegenerative disorder with growing evidence implicating gut microbiota dysbiosis in its pathogenesis. Recent research highlights the gut-brain axis as a crucial therapeutic target, with interventions such as phytotherapy, pharmacotherapy, and precision medicine emerging as promising approaches. Phytotherapy, including plant-derived compounds like curcumin and dioscin, has demonstrated neuroprotective effects by modulating gut microbiota, reducing neuroinflammation, and enhancing short-chain fatty acid production. Pharmacotherapy, particularly levodopa, remains the primary treatment for PD motor symptoms, but its interactions with gut microbiota can affect drug metabolism, necessitating microbiota-targeted strategies such as enzyme inhibitors and antibiotic co-administration. Precision interventions, including probiotics, prebiotics, synbiotics, dietary modifications, and fecal microbiota transplantation, aim to restore microbial balance and improve gut-brain axis function. This chapter explores the mechanisms, clinical outcomes, and limitations of these interventions, emphasizing the need for integrative and personalized therapeutic approaches. By targeting gut microbiota, these strategies hold potential for optimizing PD management, enhancing treatment efficacy, and improving patient quality of life.
- 3 June 2025
- Published by IntechOpen
Open AccessGut Microbiota Modulation in Parkinson’s Disease: Exploring Phytotherapy, Pharmacotherapy, and Precision Interventions
Parkinson’s disease (PD) is a progressive neurodegenerative disorder with growing evidence implicating gut microbiota dysbiosis in its pathogenesis. Recent research highlights the gut-brain axis as a crucial therapeutic target, with interventions such as phytotherapy, pharmacotherapy, and precision medicine emerging as promising approaches. Phytotherapy, including plant-derived compounds like curcumin and dioscin, has demonstrated neuroprotective effects by modulating gut microbiota, reducing neuroinflammation, and enhancing short-chain fatty acid production. Pharmacotherapy, particularly levodopa, remains the primary treatment for PD motor symptoms, but its interactions with gut microbiota can affect drug metabolism, necessitating microbiota-targeted strategies such as enzyme inhibitors and antibiotic co-administration. Precision interventions, including probiotics, prebiotics, synbiotics, dietary modifications, and fecal microbiota transplantation, aim to restore microbial balance and improve gut-brain axis function. This chapter explores the mechanisms, clinical outcomes, and limitations of these interventions, emphasizing the need for integrative and personalized therapeutic approaches. By targeting gut microbiota, these strategies hold potential for optimizing PD management, enhancing treatment efficacy, and improving patient quality of life.